https://www.selleckchem.com/products/amg-900.html
The activated clotting time (ACT) is a useful marker of unfractionated heparin (UFH) activity during cardiopulmonary bypass (CP or cardiac catheterization. Emicizumab, recently approved for bleeding prevention in haemophilia A patients, acts like FVIII but does not need prior activation; it therefore shortens coagulation times in assays using intrinsic pathway activators and so is expected to shorten the ACT. To evaluated emicizumab's impact on heparin-induced ACT (Hemochron®) prolongation. We measured the high-range (HR) ACT in citra
Like
Comment
Share
